The immunosuppressive drug, mizoribine, has been used to prevent rejection of organ allografts in humans and in animal models. Based on studies in cell lines, mizoribine has been postulated to be an inhibitor of inosine monophosphate (IMP) dehydrogenase (EC1.2.1.14), a pivotal enzyme in the formation of guanine ribonucleotides from IMP. To further characterize the mechanism of action of this drug, we studied the effect of mizoribine on human peripheral blood T cells stimulated with alloantigen, anti-CD3 MAb, or pharmacologic mitogens. Mizoribine (1-50 ,g/ml) was able to inhibit T cell proliferation by 10-100% in a dose-dependent fashion to all stimuli tested. Measurements of purine ribonucleotide pools by HPLC showed that mizoribine led to a decrease in intracellular GTP levels, and that repletion of GTP reversed its antiproliferative effects. We also examined sequential events occurring after T cell stimulation. Early events in T cell activation, as assessed by steadystate mRNA levels of c-myc, IL-2, c-myb, histone, and cdc2 kinase, as well as surface IL-2 receptor expression, were unaffected. However, cell cycle analysis revealed decreased numbers of cells in S, G2, and M phases, and showed that the G1/S block was reversed with GTP repletion. These data indicate that mizoribine has an effect on T cell proliferation by a mechanism distinct from that of cyclosporine or corticosteroids, and therefore may be useful in combination immunosuppressive regimens. (J. Clin. Invest. 1991. 87:940-948.)
Introduction
The immunosuppressive drug, mizoribine (4-carbamoyl-1-D-ribofuranosylimidazolium-5-olate, also known as bredinin), has been shown to be an effective agent in organ transplantation. In animal models, mizoribine has shown a strong synergistic effect when used in combination with cyclosporine to prolong the survival of canine renal allografts (1) (2) (3) (4) (5) , and rat cardiac and partial lung allografts (6) . Mizoribine has also been used successfully as a primary immunosuppressive agent in human renal transplantation, with results comparable or supe-(EC 1 .2.1.14), an enzyme required for the synthesis of guanine nucleotides from IMP. Initial studies demonstrated that mizoribine inhibited the growth of murine lymphoma cells by interfering with guanine nucleotide metabolism (15) . Subsequently, Ichikawa et al. found that mizoribine suppressed the proliferation of peripheral blood lymphocytes to lectins and alloantigens (16) , but specific data on its metabolic effects were not provided.
The potential importance of guanine nucleotides in T cell function is suggested by a number of findings. Signal transduction through the T cell receptor for antigen (TCR) is believed to be mediated by G protein coupling ofthe receptor to phospholipase C (17) . In addition, there is recent evidence implicating the P21"S GTPase in T cell activation (18) . Guanine nucleotides have also been suggested as second messengers in the alternate pathway of T cell activation mediated by the CD28 surface molecule, since CD28 stimulation raises intracellular cyclic guanosine monophosphate levels (19) . Finally, deficiency of the enzyme purine nucleoside phosphorylase is associated with perturbed levels of guanine ribonucleotides and severely deficient T cell immunity (20) . These observations suggest that the ability of mizoribine to block T cell proliferation might be due to its interference with physiologic guanine nucleotide metabolism, thereby blocking T cell proliferation at the level of signal transduction or at some more distal point in the activation pathway.
To further examine the effects ofmizoribine on T cell proliferation, we used purified T lymphocytes, free ofcontamination by B cells and macrophages. These accessory cell-depleted T lymphocytes do not respond to soluble antigen or lectins, but can be stimulated with monoclonal antibodies directed against either the TCR, or the CD3 complex of proteins, which is intimately associated with the TCR in the cell membrane (21) . TCR/CD3 signaling activates protein kinase C and induces a rise in intracellular calcium, effects that can be mimicked with the combination of phorbol ester and a calcium ionophore (e.g., ionomycin) (21) . The experiments described here have used both sets of stimuli in order to determine whether mizoribine interfered with cell surface signaling events or acted at a more distal point in the activation pathway.
Our studies were undertaken to ask whether mizoribine (anti-CD28), G19-4 (anti-CD3), 9.6 (anti-CD2), G17-2 (anti-CD4), and GI0. 1 (anti-CD8) were produced as previously described (22) (23) (24) (25) Isolation ofperipheral blood lymphocytes. All blood donors were healthy volunteers who gave informed consent to venipuncture. Peripheral blood mononuclear cells were isolated from venous blood by density gradient centrifugation using Ficoll-Hypaque. When specified, purified T cells were obtained using a protocol previously described (26 Northern blot analysis. Cells were harvested from cultures by resuspension and centrifugation, and total cellular RNA was extracted with guanidinium isothiocyanate (28) . The samples were equalized for ribosomal RNA, and the equalization was confirmed by ethidium bromide staining ofequal amounts of the RNA samples on a nondenaturing 1% agarose gel as previously described (29) . These equalized RNA samples (5-10 Mg) were separated on 1% agarose-formaldehyde gels and transferred to nitrocellulose. Membranes were baked under a vacuum for 2 h and then prehybridized (30) . The DNA probes used were labeled by nick translation and hybridized to the membranes as previously described (30) , after which the membranes were exposed to x-ray film at -700C.
DNA probes. The probes used in these experiments were gene-specific inserts isolated from low melting point agarose gels after digestion L. Turka Measurement ofATP and GTP. Nucleotide pools were quantified using HPLC on a Partisil-1O SAX anion exchange column (Whatman, Clifton, NJ). 5-10 x 10 cells were harvested and counted at the indicated time points, and washed twice. Cell viability, assessed by trypan blue exclusion, always exceeded 95%. The cells were then resuspended in 150 ul PBS and extracted with 170 ild ofice-cold 1 N perchloric acid.
After 5 min at 4°C, the extract was neutralized with 1 N KOH. The volume of sample analyzed was adjusted for cell count, and 50-100,M1 of the supernatant was injected for each analysis. Ribonucleoside triphosphates were separated using a linear gradient from 80% buffer A (0.002 M NH4H2PO4, pH 2.8) to 90% buffer B (0.75 M NH4H2PO4, pH 3.9) over 30 min at a flow rate of 2 ml/min. The individual nucleotide concentrations were calculated by comparing areas of peaks absorbing a.t 254 nm to the areas generated by nmol amounts of pure standards using a 3390A Hewlett Packard integrator.
Results
Mizoribine blocks mitogen and alloantigen-induced Tcell activation. Since mizoribine has been found to be effective in preventing organ allograft rejection, we first examined the effects ofthe drug on T cell proliferation induced by a variety ofmitogenic stimuli. T cells were purified as described (except for MLRs where unseparated mononuclear cells were used) and cultured with increasing concentrations of mizoribine. Table I displays a representative experiment (one of four independent experiments) showing that mizoribine blocked T cell proliferation induced by anti-CD3 MAbs, alloantigen, and PMA plus either ionomycin, anti-CD28 MAbs, or both. This effect was dose dependent, and the concentration at which 50% inhibition was seen (ICso) varied from < 1 jig/ml for CD3 stimulation, to -5 gg/ml for PMA-induced stimulation. A concentration of 50 /g/ml of mizoribine suppressed proliferation to the level of medium control for every stimulus tested. Similar results were obtained when cultures were harvested at a variety of time points before and beyond the usual culture period, demonstrating that these effects of mizoribine were not a time-dependent phenomenon (data not shown).
Mizoribine and cyclosporine additively block T cellproliferation. The fact that mizoribine inhibited T cell proliferation induced by phorbol ester plus anti-CD28 MAb (Table I) , a mitogenic combination we have previously shown to be resistant to cyclosporine immunosuppression (36) , suggested that the two drugs act via distinct mechanisms and might have an additive effect in vitro. To examine this possibility, purified T cells were stimulated with immobilized anti-CD3 MAbs in the presence of varying concentrations of mizoribine and cyclosporine. Fig. 2 shows that mizoribine and cyclosporine acted additively to inhibit proliferation induced via TCR/CD3 stimuli. For example, the combination of 5 ,ug/ml of mizoribine and 10 ng/ml of cyclosporine block proliferation to approximately the same level as is seen with 100 ng/ml ofcyclosporine alone. These in vitro findings are consistent with the observation that mizoribine and cyclosporine act cooperatively to prolong allograft survival in animal models (1, 2, 4) .
Alterations in GTP levels with mizoribine. Mizoribine has been reported to be an inhibitor of IMP dehydrogenase, an enzyme which catalyzes the first step in the conversion of IMP to guanosine monophosphate. Therefore, we next studied the effect of mizoribine on purine ribonucleotide levels in activated T cells. Purified T cells were stimulated with the combination of PMA, ionomycin, and anti-CD28 MAb. These agents were chosen since all three appear to play distinct and independent roles in T cell activation, and their combination has been previously shown to lead to maximal T cell proliferation and lymphokine production (37) . The cells were harvested 72 h after stimulation for analysis of purine ribonucleotide pools by HPLC (see Methods) and for measurement of DNA synthesis (Fig. 3) . Mizoribine caused a dose-related depletion of GTP in activated T cells (A), which closely paralleled its effect on proliferation (C). A small diminution of ATP levels (B), which did not appear to correlate with proliferative inhibition, was observed. Further evidence against a role for adenine nucleotide depletion by mizoribine was the inability of adenine supplementation of the media to reverse the proliferative inhibition of the drug (data not shown).
In order to examine the effect of lymphocyte activation on GTP levels and the time course of GTP depletion induced by mizoribine, GTP levels were serially measured in cells cultured in the presence and absence of 10 gg/ml of mizoribine (Fig. 4) . plated containing 50 IM guanosine plus 100 uM 8-aminoguanosine. We have previously shown that in cultured T and B lymphoblasts the combination of guanosine and 8-aminoguanosine at these concentrations results in a sustained rise in intracellular concentrations of GTP, whereas guanosine alone results in more transient increases (38) . This effect is mediated by the slow conversion ofguanosine to guanine in the presence of 8-aminoguanosine, a weak competitive inhibitor of the degradatory enzyme purine nucleoside phosphorylase (39). 8-Aminoguanosine alone had no effect on the mizoribine-induced inhibition ofT cell proliferation (data not shown). However, the combination of guanosine and 8-aminoguanosine augmented proliferation in the absence ofmizoribine, and completely reversed the anti-proliferative effects of mizoribine at concentrations up to 5 ,g/ml (Fig. 3, C and D) . This combination similarly reversed the inhibitory effects of mizoribine when T cells were stimulated to proliferate with anti-CD3 MAb (Fig. 3 D) . Measurement of ATP and GTP pools by HPLC confirmed that intracellular GTP levels had been restored to control values in cultures containing guanosine and 8-aminoguanosine (Fig. 3, A and B) . It is notable that at the highest doses of mizoribine used, 50 Mg/ml, the addition of guanosine and 8-aminoguanosine did not restore proliferation, despite the fact that GTP levels were unchanged. This was not due to a direct toxic effect of the drug, since cell viability as assessed by trypan blue exclusion was not altered by this dose of mizoribine. Rather, it suggests that mizoribine may have additional mechanisms of action which are physiologically important only at high concentrations of the drug. Mizoribine does not interfere with early events in T cell activation. The traditional assay of proliferation by DNA synthesis measures an event that occurs during S phase of the cell cycle. Having found that mizoribine blocked DNA synthesis, we now sought to determine whether events occurring earlier in the cell cycle (i.e., in G 1) were similarly inhibited. Thus purified T cells were stimulated with PMA plus ionomycin plus anti-CD28 MAb in the absence or presence of 10 ,ug/ml of mizoribine, and the cells were harvested at 6 and 24 h. Total cellular RNA was extracted and analyzed by Northern blotting (Fig. 5) . A concentration of 10 ,ug/ml of mizoribine was used since this exceeded the ICm ofthe drug for this particular mitogenic stimulus. In the experiment shown, proliferation (measured on day 3) was inhibited by 71% (14,869±1589 vs. 4272±512). As shown in Fig. 5 mizoribine did not block the expression of the nuclear protooncogene, c-myc, a gene expressed very early after T cell activation, independent of new protein synthesis (40) . To determine whether mizoribine blocked entry ofthe cells into the G 1 phase ofthe cell cycle we also analyzed steady-state mRNA levels for cdc2 kinase, a gene expressed at the R (restriction) point in G 1, after which the cell becomes committed to mitosis and is unable to return to GO (41) . As was the case for c-myc, cdc2 kinase levels were not significantly altered in mizoribine-treated cultures (Fig. 6) . Mizoribine also did not affect the expression of either histone or c-myb, both of which are expressed late in G1 (data not shown) (4 1).
IL-2 and IL-2R expression is unimpaired by mizoribine. Since mizoribine did not appear to interfere with the general process of T cell activation, we next asked whether mizoribine interfered with the specific induction ofthe T cell growth factor IL-2 or its receptor (IL-2R). To test for IL-2 expression Northern blots prepared as above were hybridized with an IL-2-specific cDNA probe (Fig. 5) c-myc and cdc2 kinase mRNA levels, mizoribine did not block the expression of IL-2 mRNA. The small increase in IL-2 mRNA seen in the mizoribine-treated culture is accounted for by the slightly higher amount of HLA message found in that sample.
Flow cytometry was used to measure IL-2R induction, and as shown in Fig. 7 no significant effect on surface IL-2R expression was seen at concentrations ofmizoribine up to 10 gg/ml in cells stimulated with PMA plus ionomycin plus anti-CD28 MAb. Mizoribine did not affect the forward or side light scatter profiles of cells harvested from these cultures, indicating again that T cells became activated with a concomitant increase in size and granularity. Similar results were obtained when T cells were stimulated with anti-CD3 MAb (data not shown). In addition, mizoribine did not alter the percentage of lymphoblasts that stained positive for CD4, CD8, CD28, or the TCR # chain (data not shown). At a concentration of 50 ug/ml of mizoribine, moderate decreases in both IL-2R expression and light scatter were seen. This observation, coupled with the inability of GTP repletion to reverse the proliferative inhibition of 50 ,gg/ml of mizoribine (Fig. 3) , further suggests there may be additional mechanisms ofaction ofmizoribine at high concentrations.
Mizoribine blocks the movement ofcellsfrom GJ to Sphase ofthe cell cycle. Since it was demonstrated that mizoribine did not block the initial steps of T cell activation, we utilized cell cycle analysis to further characterize the point at which mizoribine inhibited T cell proliferation. Cells were stimulated with anti-CD3 MAb, harvested after 48 h, and stained with propidium iodide before flow cytometry. As seen in Fig. 8 (A and C) , cultures containing mizoribine contained significantly decreased numbers of cells in S, G2, and M phases of the cell cycle. Supporting the importance of this observation, GTP repletion using guanosine plus 8-aminoguanosine restored the normal progression to S phase in mizoribine-treated cultures (Fig. 8, B and D) . Since mizoribine did not block the expression ofthe G I -associated genes, c-myc and IL-2, this result confirms that mizoribine blocks the movement of cells from GI to S. (44) . The imidazole nucleoside mizoribine was first isolated from a soil fungus in 1974, and since then has proven efficacious in both clinical and experimental transplantation. Despite this, little is known ofits mechanism ofaction. Our results demonstrate that mizoribine blocks the proliferation of T cells to a variety of mitogenic stimuli, without interfering with the initial phases of T cell activation.
The ability of mizoribine to inhibit T cell proliferation induced by either mitogens, which engage cell surface structures (e.g., anti-CD3 MAb or alloantigen), or by phorbol ester plus calcium ionophore, indicates that the effect of the drug is independent ofcell membrane interactions and occurs after protein kinase C activation and intracellular calcium increases. Our findings that the expression of c-myc and IL-2 mRNA, and of the 55-kD IL-2R protein product is consistent with these observations, and demonstrates that mizoribine does not affect events occurring in the initial phases of G1. This finding was confirmed by cell cycle analysis which demonstrated that mizoribine-containing cultures had decreased numbers of cells in S, G2, and M phases, thus indicating a blockade in the movement of cells from G1 to S. Since the expression of mRNA for cdc2 kinase, histone, and c-myb were each unaltered by mizoribine, the block can be further localized to a subphase late in G1 and distal to the R (restriction) point, after which cells become committed to mitotic division.
T cell unresponsiveness to IL-2, even in the presence of IL-2R expression, has been reported in other systems and is potentially a physiologic immunoregulatory mechanism (45) . Consistent with this, the interaction of IL-2 with its receptor has been shown to induce c-myb expression and stimulate the progression ofcells from G I to S phase (46). Churilla et al. (47) have reported that in antigen-stimulated T cell clones, the failure of IL-2R+ cells to proliferate in response to IL-2 correlates with a lack of c-myb expression. In this study, mizoribine was also able to block the proliferation of naive T cells, despite the sparing of IL-2 and IL-2 receptors. This effect however, must occur by a distinct mechanism, since we found no impairment ofc-myb induction, implying that at least part of IL-2 signaling was unimpaired.
In an attempt to more precisely define the mechanism of action ofthe drug, we examined intracellular purine ribonucleotide pools, since mizoribine has been postulated to inhibit IMP dehydrogenase, an enzyme required for guanine nucleotide biosynthesis. These studies showed that mizoribine caused a dose-dependent depletion ofintracellular GTP without significantly affecting ATP. When intracellular GTP was repleted using the combination of guanosine and 8-aminoguanosine, the antiproliferative action ofmizoribine was reversed at all but the highest doses of the drug. Thus at low to moderate concentrations of mizoribine, inhibition ofproliferation appears to be a direct consequence of GTP depletion. In contrast, at higher concentrations of mizoribine (50 ,g/ml), we were unable to reverse the antiproliferative effects ofthe drug with GTP repletion, despite restoration of GTP levels to control values. As discussed earlier, we conclude that there may be additional mechanisms of action of mizoribine at high concentrations.
We did not observe depletion of adenine nucleotide pools at concentrations of mizoribine up to 10 ug/ml, and adenine did not reverse the inhibitory effects of the drug (data not shown). Thus, our data provide direct evidence regarding the importance of GTP in T cell proliferation. Previous studies on cells from patients with purine nucleoside phosphorylase defi-ciency, all ofwhom have severely depressed cellular immunity, have demonstrated a depletion in GTP in the erythrocytes from some ofthese individuals (48, 49) . However to our knowledge, this is the first report directly examining the effects of GTP depletion and repletion on T cell activation and proliferation. It is of additional interest that while the site of action of azathioprine remains unknown despite extensive study and clinical use (44) , its active metabolite, 6-thio-IMP, is capable of inhibiting IMP dehydrogenase (50) , thereby causing changes in intracellular purine ribonucleotides similar to what we have observed with mizoribine. Of the known inhibitors of IMP dehydrogenase, only mycophenolic acid and tiazofurin have been used in large clinical trials. Mycophenolic acid has been moderately effective in the treatment of psoriasis (51), but was withdrawn from widespread use because ofgastrointestinal toxicity. Tiazofurin was developed as an antineoplastic agent, but was associated with marked toxicity in phase I studies (52) . The potential of either of these drugs to act as immunosuppressive agents has not been specifically evaluated.
As supported by our data (Fig. 2) and in vivo studies, mizoribine might be expected to be most useful in human allograft recipients when combined with cyclosporine and corticosteroids. An advantage of this regimen is that mizoribine does not appear to cause either myelosuppression or hepatotoxicity, both of which can occur with azathioprine. At doses of 1-3 mg/kg per d, mizoribine has proven safe and efficacious in human renal transplantation (4, (7) (8) (9) (10) (11) (12) . When measured, peak and trough mizoribine levels have been -5 and 1 gg/ml, respectively, concentrations that we have shown to act additively with cyclosporine in vitro. Our finding that mizoribine blocked GTP accumulation even when added after cell stimulation (Fig. 4) , coupled with the observation that cell proliferation is similarly inhibited by exposure to mizoribine during the final hours ofculture (16; and data not shown), suggests that mizoribine might be useful in modulating active immune responses as well as in preventing their initiation.
In conclusion, we have shown that mizoribine blocks T cell proliferation without interfering with proximal events in T cell activation. The mechanism of action of mizoribine, when used in low doses, is depletion of intracellular GTP pools, which causes a block in transition of the cells from G 1 to S phase in the cell cycle. While GTP depletion is known to be associated with inhibition of DNA synthesis per se (53), the lack ofmyelosuppression in patients treated with mizoribine argues against a non-specific antiproliferative effect at the doses used clinically. The apparent selective effect ofthis drug against T cells in vivo may be related either to their relative levels of IMP dehydrogenase or to their more specific requirements for GTP. We are currently using in vitro models of lymphoid and nonlymphoid cell growth to confirm a T cell-specific effect of mizoribine and to examine the basis for this specificity.
